SCHEDULE: RA Capital Reduces VOR BioPharma Stake

RA Capital Management and its affiliates have significantly reduced their beneficial ownership in VOR BioPharma Inc. through recent open market sales.

Summary

• RA Capital Management, L.P. and its affiliates filed Amendment No. 9 to their Schedule 13D for VOR BioPharma Inc.
• The reporting persons, including RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P., collectively hold 11.5% of VOR BioPharma's common stock.
• RA Capital Healthcare Fund, L.P. directly holds 779,652 shares, along with warrants for up to 1,056,072 common shares and pre-funded warrants for up to 10,000,000 shares.
• Beneficial ownership blockers prevent the exercise of warrants if it would result in ownership exceeding 9.99% of outstanding common stock, and the Fund is currently prohibited from exercising due to these blockers.
• Between October 28, 2025, and October 30, 2025, RA Capital Healthcare Fund, L.P. sold a total of 400,408 shares of VOR BioPharma common stock in open market transactions.
• Sale prices ranged from $25.00 to $28.335 per share, with weighted average prices of $27.10, $28.18, $25.22, and $25.12 for the respective transaction dates.
• The percentage of class represented by RA Capital's aggregate beneficial ownership is based on 6,853,907 shares outstanding as of September 18, 2025.

Sentiment

Score: 3

Explanation: The significant reduction in stake by a major institutional investor, RA Capital, is generally viewed negatively by the market as it can signal a loss of confidence or a strategic exit, even if the underlying company performance is not directly addressed in this filing. The presence of beneficial ownership blockers also highlights a structural limitation on potential future investment increases from this entity.

Negatives

• A significant institutional investor, RA Capital Healthcare Fund, L.P., sold 400,408 shares of VOR BioPharma common stock over three days.
• The sales occurred at prices ranging from $25.00 to $28.335, indicating a reduction in exposure by a major holder.

Risks

• The presence of "Beneficial Ownership Blockers" in warrants limits the ability of RA Capital Healthcare Fund, L.P. to increase its direct equity stake beyond 9.99%, potentially restricting future investment flexibility or influence.
• Significant sales by a major institutional investor could signal a lack of confidence or a strategic portfolio rebalancing, which may negatively impact investor sentiment and share price.

Future Outlook

NA

Industry Context

This filing reflects a portfolio adjustment by a specialized healthcare investment fund, RA Capital, which is common in the dynamic biotechnology sector. Such adjustments can be driven by various factors including investment thesis changes, capital reallocation, or risk management, rather than necessarily reflecting specific negative news about the issuer. However, significant sales by a prominent biotech investor can sometimes be interpreted by the market as a signal, potentially influencing broader sentiment towards similar early-stage biopharma companies.

Legal Proceedings

• None of the Reporting Persons has been a party to a civil or criminal proceeding during the last five years.

Stakeholder Impact

• Shareholders: Potential negative impact on share price due to reduced institutional ownership and potential signal of decreased investor confidence.
• Management: May face increased scrutiny regarding company performance and future strategy following a major investor's stake reduction.

Key Dates

Recommendation

While a significant institutional investor has reduced its stake, this filing alone does not provide sufficient information on VOR BioPharma's operational performance, clinical pipeline, or financial health to warrant a 'sell' recommendation. The reduction could be due to portfolio rebalancing rather than a fundamental change in the company's prospects. Investors should 'hold' and await further company-specific updates or financial reports to make a more informed decision, while acknowledging the potential negative sentiment from this filing.

Keywords

VOR BioPharma, RA Capital Management, Schedule 13D/A, Beneficial Ownership, Stock Sales, Institutional Investor, Biopharma, Warrants, Equity Stake